Pseudoachalasia is a condition in which clinical and manometric signs of achalasia are mimicked by another abnormality, most often a malignancy.
SUMMARY Background
Pseudoachalasia is a condition in which clinical and manometric signs of achalasia are mimicked by another abnormality, most often a malignancy.
Aim
To identify risk factors that suggest presence of malignancy-associated pseudoachalasia.
Methods
In this retrospective cohort study, achalasia patients newly diagnosed by manometry were included. Patients with a normal initial endoscopy, clinical and manometric signs of achalasia who were afterwards found to have an underlying malignant cause were classified as pseudoachalasia. Clinical and diagnostic findings were compared between malignant pseudoachalasia and achalasia.
Results
We included 333 achalasia patients [180 male, median age 50 (38-62)]. Malignant pseudoachalasia was diagnosed in 18 patients (5.4%). Patients with malignancy-associated pseudoachalasia were older at time of diagnosis [67 (54-71) vs. 49 (37-60) years], had a shorter duration of symptoms [6 (5-10) vs. 25 ) months] and lost more weight [12 (9-17) vs. 5 (0-12) kg). In 61% of the pseudoachalasia patients, the oesophagogastric junction (OGJ) was difficult or impossible to pass during endoscopy, compared to 23% in achalasia. Age ≥55 years (OR 5.93), duration of symptoms ≤12 months (OR 14.5), weight loss ≥10 kg (OR 6.73) and difficulty passing the OGJ during endoscopy (OR 6.06) were associated with a higher risk of malignant pseudoachalasia.
Conclusions
Advanced age, short duration of symptoms, considerable weight loss and difficulty in passing the OGJ during endoscopy, are risk factors that suggest potential malignancy-associated pseudoachalasia. To exclude pseudoachalasia, additional investigations are warranted when two or more risk factors are present. 
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INTRODUCTION
Idiopathic achalasia is a primary motility disorder of the oesophagus caused by loss of neurons in the myenteric plexus which induces aperistalsis and impaired relaxation of the lower oesophageal sphincter (LOS). Patients typically present with dysphagia, regurgitation of food, chest pain and weight loss. 1 Manometry is the gold standard to diagnose achalasia. Pseudoachalasia is a condition in which clinical and manometric features of idiopathic achalasia are mimicked by another abnormality, most often a malignancy. In 1947, Ogilvie was the first to describe that malignant involvement of the oesophagus can resemble idiopathic achalasia. 2 Since this observation, many case reports and series are published that describe this phenomenon with a diversity of underlying causes. In 70% of the patients with pseudoachalasia, a primary or secondary malignancy is involved. 3, 4 The most common causative tumours of pseudoachalasia are a carcinoma of the oesophagus or cardia. [3] [4] [5] [6] [7] [8] [9] Pseudoachalasia can also be seen as a paraneoplastic manifestation of malignancies. 10 It is important to recognise pseudoachalasia early to prevent inappropriate therapeutic intervention and delay in appropriate treatment. However, identification of pseudoachalasia is challenging because both clinical and diagnostic features are comparable to idiopathic achalasia. The diagnostic approach of patients suspected for achalasia starts with endoscopy and in case no abnormalities are seen, a manometry and barium oesophagogram are performed. In literature, it is described that manometry cannot distinguish between achalasia and pseudoachalasia and that the barium oesophagogram is of limited value in discriminating between the two. 4, 11 Endoscopy seems a reliable tool to diagnose tumours or strictures of the oesophagus or cardia. However, a tumour can only be diagnosed by endoscopy if it passes the submucosal layer, which is highly variable per patient. Thus, discriminating between achalasia and malignancy-associated pseudoachalasia seems challenging with the standard diagnostics. The aim to prevent missing malignant pseudoachalasia leads to many requests for additional radiological imaging and endoscopic ultrasound resulting in high costs and a burden to patients, while only 4-5% of the endoscopic-negative patients manometrically diagnosed with achalasia appears to have pseudoachalasia. 3, 4 Obviously, early recognition of malignancy-associated pseudoachalasia is important to prevent delay in appropriate treatment. However, reliable discriminating features for pseudoachalasia are lacking. Therefore, the aim of this study was to identify risk factors that suggest presence of malignancyassociated pseudoachalasia that warrant additional investigation.
MATERIALS AND METHODS
Subjects and inclusion criteria
For this retrospective cohort study, we included adult patients (≥18 years) in whom a new manometric diagnosis of achalasia was made in our centre between January 2000 and December 2014. Manometric criteria for achalasia were defined as absent peristalsis and impaired relaxation of the LOS. During the study period, the technique of the manometry catheters evolved, from conventional (water-perfused catheter, with perfused Dent sleeve) to high-resolution manometry (solid-state, HRM), but the standardised protocol for assessing oesophageal motility remained similar. The catheter was placed transnasally and positioned such that it recorded from hypopharynx to the stomach. During manometry, patients were in supine position and swallowed 10 water boluses of 5 mL with an interval of 20 s. For conventional manometry impaired LOS relaxation was defined as less than 50% relaxation relative to the basal LOS pressure or a nadir pressure ≥10 mmHg during swallowinduced relaxation. 12 Impaired LOS relaxation during HRM was determined by an integrated relaxation pressure >15 mmHg. 13 This study was evaluated by the local Medical Ethical Committee and approved (August 2013, number W13_180#13.17.0225).
Pseudoachalasia
Patients were classified as having pseudoachalasia when the initial endoscopy showed no relevant mucosal abnormalities, clinical and manometric signs were typical for achalasia, no operations or other conditions in the past that are known to induce oesophageal obstruction such as fundoplication, oesophageal trauma surgery and gastric banding were present and only later during additional testing or treatment a malignant lesion was found to be the underlying cause.
Data collection and analysis
Medical records of eligible patients were reviewed. Clinical, endoscopic, manometric and radiological findings were evaluated and described. Type of symptoms was assessed and the Eckardt symptom score was used to express the severity of symptoms. This score reflects the sum of symptom scores for dysphagia, regurgitation and chest pain (0 = absent, 1 = occasionally, 2 = daily, 3 = each meal) with additionally the score of weight loss (0 = no weight loss, 1 = <5 kg, 2 = 5-10 kg, 3 = >10 kg).
14 Duration of symptoms was determined by the onset of the first symptoms until the initial diagnosis of achalasia by manometry. For endoscopy, we assessed whether there was stasis of liquids/foods in the oesophagus, a dilated oesophagus, mucosal abnormalities or difficulties passing the oesophagogastric junction. Any biopsies that were taken were described. For manometry, the following features were analysed; type of manometry, oesophageal contraction pattern, basal LOS pressure and if available LOS relaxation pressure or integrated relaxation pressure. All radiological investigations that were performed to diagnose achalasia or pseudoachalasia were analysed. As part of the diagnostics of achalasia, patients underwent an oesophageal video fluoroscopy or a timed barium oesophagogram to assess oesophageal emptying. Delayed emptying of contrast, narrowing of the oesophagogastric junction, distension of the oesophagus and barium column height in case of stasis were noted. Achalasia treatment was evaluated and the type of treatment was described in case it was performed in patients with pseudoachalasia before the underlying cause was revealed. The investigation that eventually revealed the underlying cause of pseudoachalasia was reported. Data of achalasia patients were compared to patients with malignancy-associated pseudoachalasia, to identify risk factors for pseudoachalasia.
Statistical analysis
Continuous data are presented as median (interquartile range, IQR) according to distribution. Categorical data are presented in percentages. Data of achalasia patients and patients with malignant pseudoachalasia, were compared using Mann-Whitney U-test in case of continuous data and Chi-square test or Fisher's exact for categorical data. Differences were considered statistically significant when P < 0.05. All reported P-values are two-tailed. Receiver operating characteristic curves were plotted for continuous variables that raised a significantly higher suspicion of pseudoachalasia, to determine optimal cutoff values. The optimal cut-off value was defined as the cut-off corresponding to the point of the receiver operating characteristic curve closest to the sensitivity = 1 specificity = 1 optimum. For each applicable variable, the optimal cut-off and area under the curve of the receiver operating characteristic curve were displayed. Univariable logistic regression analysis was performed, to observe if obtained cut-off values were useful indicators to discriminate between pseudoachalasia and achalasia, expressed as odds ratio (OR) with corresponding 95% confidence intervals (CI). Interacting variables were checked using multivariable analysis. For the multivariable analysis, variables were selected based on content validity described in previously literature and a significant P-value (P < 0.05). Statistical analysis was performed using IBM SPSS Statistics 21 (IBM Corporation, Armonk, NY, USA).
RESULTS
Study inclusion
From January 2000 until December 2014, 562 individual patients with idiopathic achalasia were seen at the clinic. Of these patients, 221 were excluded because the primary diagnosis was made before the year 2000 (n = 147), they were diagnosed at childhood (n = 20), another motility disorder was diagnosed (n = 52) or achalasia was part of the Triple A syndrome (n = 2). Eight patients were identified with a benign cause of pseudoachalasia (gastric banding; Nissen fundoplication; leiomyoma; 2 9 fibrosis by thorax trauma (stabbing); fibrosis post-radiotherapy for bilateral breast carcinoma; stenotic peptic lesion). These patients were excluded from the analysis because prior medical history made secondary achalasia very likely and the aim of the study was to select patients in which this was not the case. In the end, 333 patients [180 male, age 50 (38-62) years] were included for final analysis.
Pseudoachalasia
Of the 333 patients diagnosed with achalasia, 18 patients (5.4%) were diagnosed with malignant pseudoachalasia. Table S1 (added as Supporting Information) shows the clinical and diagnostic findings of the 18 patients with malignancy-associated pseudoachalasia. In all cases symptoms of achalasia were caused by tumour compression and invasion. None of the patients had a paraneoplastic syndrome. In 89% of our patients, a primary malignancy caused pseudoachalasia and in the other two patients mediastinal/peritoneal metastasis of breast cancer gave rise to pseudoachalasia. Both patients were previously curatively (7 and 9 years disease free) treated for breast cancer by mastectomy combined with chemo-and radiotherapy. Gastric adenocarcinoma was observed in 33% (n = 6) of the patients with pseudoachalasia, oesophageal adenocarcinoma in 28% (n = 5), oesophageal squamous cell carcinoma in 17% (n = 3) and 11% (n = 2) had an adenocarcinoma of the pancreas tail. In none of the patients, the initial endoscopy had revealed malignancy. However, in 61% the oesophagogastric junction was difficult to pass and in seven patients inflamed, erosive mucosa was seen in the distal oesophagus. In two of seven patients, it was interpreted as reflux oesophagitis. Biopsies revealed no abnormalities (64%) or mild to severe inflammation (36%). Stasis of food was seen in 22% of the patients. In all patients, manometry was typical of achalasia. Basal LOS pressure was normal, 33 (22-39) mmHg, but relaxation was not [LOS relaxation pressure (n = 3) 25 (13-25 mmHg) and integrated relaxation pressure (n = 8) 26 (23-37) mmHg]. The contraction pattern was failed in three patients, simultaneous in eight patients and panoesophageal pressurisation was observed in seven patients. Oesophagogram (n = 16) was typical for achalasia in 75% of the patients, showing stasis and/or a widened oesophagus.
The interval between manometry and diagnosis of pseudoachalasia varied considerably (range 0 days-5 months). In 28% (n = 5) of the patients, pseudoachalasia was eventually diagnosed by a second or third endoscopy with biopsies, in 28% (n = 5) by CT scan of thorax/abdomen, in 16% (n = 3) by endoscopic ultrasound and in 28% (n = 5) during achalasia treatment (four times during pneumodilation and one time during Heller myotomy). Four of the 10 patients diagnosed by endoscopy or CT scan, had already undergone achalasia treatment with botulinum toxin injections and/or pneumodilation. The total number of investigations that needed to be performed before pseudoachalasia was diagnosed ranged from 4 to 10, with a median of 6 (5-7).
Curative resection was performed in seven patients with an oesophageal or cardia carcinoma. All other patients underwent palliative treatment, radiotherapy and/or chemotherapy.
Malignancy-associated pseudoachalasia vs. achalasia Clinical and diagnostic findings. As shown in Tables 1  and 2 , there were several differences in presentation and diagnostic findings between patients with malignant pseudoachalasia and achalasia. Patients with pseudoachalasia were older at the time of diagnosis [67 (54-71) years vs. 49 (37-60) years, P < 0.001). There were no differences observed in the symptoms dysphagia, regurgitation, chest pain and dyspepsia that were reported. However, heartburn was never reported by patients with malignancy-associated pseudoachalasia, compared to 28% of the achalasia patients (P < 0.01). Analysing symptoms using the Eckardt symptom score, we observed a significantly higher score in patients with malignant pseudoachalasia [9 (8-10) vs. 7 (6-9), P < 0.01]. However, when the Eckardt symptom score was calculated without including weight loss no difference was seen between malignancy-associated pseudoachalasia and achalasia [6 (6-7) vs. 6 (5-7), P = 0.06]. Patients with pseudoachalasia had a shorter duration of symptoms compared to achalasia patients [6 (5-10) months vs. 25 (12-60) months, P < 0.001) and lost significantly more weight [12 (9-17) kg vs. 5 (0-12) kg, P < 0.01]. In 61% of the patients with malignant pseudoachalasia, the oesophagogastric junction was difficult or impossible to pass during endoscopy, compared to 23% in achalasia (P < 0.001). Manometric studies in both groups were typical of achalasia. No differences were observed in basal LOS pressure, relaxation pressure, contraction pattern or achalasia subtype. An oesophagogram was performed in 16 patients with malignant pseudoachalasia. In 75% of the patients, it was suggestive of achalasia which was significantly lower compared to the 94% in achalasia (P < 0.01). This difference could be explained by the lower proportion of patients with malignant pseudoachalasia showing stasis at the oesophagogram compared to achalasia (75% vs. 94%, P < 0.01).
Cut-off values clinical variables and risk analysis. The clinical variables age, duration of symptoms and weight loss were significantly different between malignancyassociated pseudoachalasia and achalasia. Optimal cut-off values were determined for these continuous variables using receiver operating characteristic curves to optimise differentiation between malignant pseudoachalasia and achalasia ( Figure 1 ). For age at diagnosis, the receiver operating characteristic curve showed that 55 years yielded the optimal combination of sensitivity and specificity. The area under the receiver operating characteristic curve was 0.75 (95% CI: 0.65-0.86, P < 0.001).
Assessing the receiver operating characteristic curve for duration of symptoms, the optimal cut-off value was determined at 12 months with an area under the curve of 0.85 (95% CI: 0.74-0.95, P < 0.001). The optimal cutoff value for weight loss was 10 kg with an area under the curve of 0.72 (95% CI: 0.63-0.82, P < 0.01). Table 3 shows that over 70% of the patients with malignant pseudoachalasia are within the created cut-off values, compared to less than 40% of achalasia patients (P < 0.01). Univariable analysis of the clinical cut-off values and previous significant diagnostic variables showed that both clinical and diagnostic variables were risk factors for pseudoachalasia (Table 3) . Assessing the independent effect of each risk factor with multivariable analysis, age ≥55 years, duration of symptoms ≤12 months, weight loss ≥10 kg and difficulty passing the oesophagogastric junction by endoscopy were associated with a higher risk of having pseudoachalasia (Table 3 ). Stasis at oesophagogram did not seem to be an independent diagnostic risk factor. Table 4 and Figure 2 show the distribution of patients focused at the number of positive clinical risk factors or combined clinical and diagnostic risk factors in malignancy-associated pseudoachalasia vs. achalasia. 88% of the patients with malignant pseudoachalasia had two or more clinical risk factors compared to only 25% in the achalasia group. Two patients with malignant pseudoachalasia had only one clinical risk factor, which was substantial weight loss and short duration of symptoms, respectively. When adding the diagnostic risk factor, difficulty passing the oesophagogastric junction by endoscopy, 100% of the malignant pseudoachalasia patients had two or more risk factors compared to only 35% of the achalasia patients. A high specificity (77-99.7%) and reasonable sensitivity (28-50%), with a fair to good positive predictive value (6-80%) was observed when two or more risk factors were present. Based on these data, a cut-off of two or more factors for the combined clinical and diagnostic risk factors seemed indicative of an increased risk of malignancy-associated pseudoachalasia.
Frequency of additional imaging in achalasia. Additional imaging by CT scan or endoscopic ultrasound was performed in 107 (34%) achalasia patients. Of these patients, 88 underwent either a CT scan (n = 43) or endoscopic ultrasound (n = 45) and 16 underwent both investigations. One patient underwent a CT scan three times and in two patients, four investigations were performed which were all negative for pseudoachalasia. In 49% of the achalasia patients, imaging was performed in case of zero (nine patients) or one (43 patients) positive clinical risk factor. Taking both clinical and diagnostic risk factors into account, in 41 (38%) patients a CT scan, endoscopic ultrasound or both were executed while zero or one risk factor for pseudoachalasia was present. In 69 (22%) patients, a chest X-ray and/or abdominal ultrasound were performed, all without abnormalities.
DISCUSSION
In this retrospective cohort study, we wanted to identify risk factors that can help discriminate between malignant pseudoachalasia and achalasia. The results indicate that age ≥55 years, a duration of symptoms ≤12 months, weight loss ≥10 kg and difficulty in passing the oesophagogastric junction during endoscopy, are risk factors that suggest potential malignancy-associated pseudoachalasia. We suggest that additional investigations are warranted when achalasia patients have two or more of these risk factors present. Conventional diagnostics for achalasia such as manometry and oesophagogram, are not useful for differentiation between pseudoachalasia and Figure 2 | Risk of malignant pseudoachalasia based on the number of risk factors. The percentage of patients with malignant pseudoachalasia (n = 18) or achalasia (n = 315) depending on the number of risk factors displayed. The probability of malignant pseudoachalasia increased when 2 or more risk factors were present.
achalasia. From our study, we could not conclude which type of investigation should be used to detect pseudoachalasia, as cases were identified with repeated endoscopy, endoscopic ultrasound and CT.
Compared to the current literature, this study described the largest cohort of malignant pseudoachalasia patients. 3, 4, 6, [15] [16] [17] Between 2000 and 2014, 18 patients with malignancy-associated pseudoachalasia were diagnosed which was 5.4% of all achalasia patients. These proportions are comparable to previous studies that described rates of pseudoachalasia between 1.5% and 4.7%. 3, 4, 6, 15 Comparing clinical features of malignant pseudoachalasia with achalasia, we observed that advanced age, short duration of symptoms and considerable weight loss were suggestive of malignancy-associated pseudoachalasia. No differences were observed in the type of symptoms. However, when symptoms were classified according to the Eckardt score, there was a significant higher score in the pseudoachalasia group compared to achalasia which was not previously described. However, weight loss, which is also taken into account in this score, seemed to be the culprit. When the Eckardt score was corrected for weight loss, no difference was observed. The clinical characteristics that seemed useful indicators of pseudoachalasia were similar to the features described in earlier studies. 3, 5, 6, 9, 15, 17 However, previous studies omitted to identify useful and relevant cut-off values for the clinical risk factors. The established cut-off values; age ≥55 years, a duration of symptoms ≤12 months and weight loss ≥10 kg respectively, showed a reasonable specificity which makes it useful tools in the clinical decision making whether or not to perform additional investigations to exclude pseudoachalasia. In addition to clinical risk factors, we also searched for diagnostic risk factors. Conventional diagnostics for achalasia, manometry and barium oesophagogram, could not distinguish between malignant pseudoachalasia and achalasia. Regardless whether conventional or high-resolution manometry was used, in both pseudoachalasia and achalasia absence of peristalsis with a normal to high basal LOS pressure and dysrelaxation of the LOS was observed. No objectified stasis during an oesophagogram seemed suggestive of pseudoachalasia. However, when adjusted for interacting variables with multivariable analysis this difference was not observed and therefore not qualified as a risk factor. Interestingly, previous studies showed that a narrowed distal oesophageal/oesophagogastric junction segment of ≥3.5 cm with asymmetry and filling defects or an oesophageal diameter of 4 cm or less at its widest point, was suggestive of pseudoachalasia. 6, 11, 18 In none of our patients, these signs were present. Our study showed that difficult or no passage of the oesophagogastric junction at initial endoscopy was suggestive of pseudoachalasia, similar to the findings of Tracey et al. 19 Comparable to other studies, no other endoscopic findings could distinguish between pseudoachalasia and achalasia. 3, 4, 9 Biopsies should always be taken if endoscopic passage of the oesophagogastric junction is difficult. However, there is a reasonable chance of false negativity as also shown in our study. This emphasise the importance to take into account all risk factors instead of one and consider redo-endoscopy in case of a difficult endoscopic passage. Differentiation between malignancy-associated pseudoachalasia and achalasia clearly increased with the presence of two or more risk factors, this accounted for 100% in pseudoachalasia compared to 36% in achalasia. The risk factors showed a reasonable sensitivity (0-50%), with a high specificity (59-99.7%) to exclude pseudoachalasia when all risk factors were present. The positive predictive value ranged from 0% at the presence of one risk factor to 80% for all risk factors. The relative low prevalence of pseudoachalasia in this cohort resulted in a moderate positive predictive value, which indicates that these risk factors could lead to overdiagnosing possible pseudoachalasia in achalasia patients. However, it may be argued that this is better than missing a diagnosis of cancer. On the basis of the data, we conclude that an achalasia patient is at risk for pseudoachalasia when two or more risk factors are present and consequently warrants additional investigations. Like in other series, several of our pseudoachalasia patients were diagnosed during achalasia treatment or even afterwards. 4, 6, 9 This emphasises the difficulty to differentiate between malignant pseudoachalasia and achalasia. In none of the pseudoachalasia patients, the initial endoscopy revealed a malignancy. All tumours probably involved the muscle layers and/or submucosa without disrupting the mucosa, hampering endoscopic visualisation. From our data, it seemed that a second/ third endoscopy or CT scan effectively diagnosed pseudoachalasia. However, 40% of these patients had already undergone achalasia treatment and additional diagnostics were performed because of recurrent symptoms. Twelve patients with malignant pseudoachalasia underwent a CT scan, in only five patients it revealed the malignancy. Endoscopic ultrasound was assessed in five patients and in three of these patients pseudoachalasia was diagnosed. Therefore, from our study we could not recommend a specific type of investigation that explicitly should be used to diagnose pseudoachalasia. The American College of Gastroenterology advises to perform endoscopic ultrasound in case pseudoachalasia is suspected. 20 Endoscopic ultrasound can rule out not only an infiltrating tumour but also provide supportive evidence of achalasia when a thickened circular muscle layer is observed. 20, 21 Other advantages of endoscopic ultrasound are that biopsies can be taken, there is no exposure of ionising radiation and it can easily be performed in conjunction with an endoscopy or pneumodilation. 21, 22 Licurse et al. showed that the CT scan is also useful for differentiating pseudoachalasia from achalasia. 23 In case of pseudoachalasia, asymmetric oesophageal wall thickening, a mass around the oesophagogastric junction and mediastinal lymphadenopathy can be found. 23 A major advantage of CT scan is that metastases can be observed and tumours causing achalasia as part of a paraneoplastic syndrome. 23 The four pseudoachalasia patients that underwent achalasia treatment all experienced quick recurrence of symptoms. Additional diagnostics should always be performed in patients with recurrent symptoms shortly after treatment. Imaging by CT scan or endoscopic ultrasound was performed in 107 (34%) achalasia patients. Interesting, 38% of these patients were according to our data not at risk for pseudoachalasia because less than two risk factors were present. In the future additional imaging should be more restrained in this group. Besides that the identified risk factors can prompt addition to diagnostic investigations in patients with multiple risk factors present, it can also help to reduce performing additional tests in other patients. The observation that all pseudoachalasia patients had at least two risk factors present suggests that additional testing is not required in patients with none or just one risk factor. This would lead to a significant reduction in the number of endoscopic ultrasounds and CT scans, reducing patients discomfort, radiation exposure and costs to society.
This study has limitations. First, it is a retrospective study and for the collection of data we focused on available reports, investigations and patient records. Consequently, in some cases, interpretation of the data was needed which could have caused information bias. We minimised this by reviewing the data twice by two independent researchers. A second potential limitation is the relative small number of patients with malignant pseudoachalasia. However, the number of cases was larger than described in previous studies. The limited cases influenced the type of statistical analysis that was performed. The aim of the study was not to develop a prediction model for pseudoachalasia, but to give insight in the causality of risk factors that possible indicate pseudoachalasia. Therefore, in the multivariable analysis only variables with a P < 0.05, confirmed by content validity based on previously literature, were included.
In conclusion, advanced age (55 years or older), short duration of symptoms (12 months or less), considerable weight loss (10 kg or more) and difficulty in passing the oesophagogastric junction during endoscopy, are risk factors that suggest potential malignancy-associated pseudoachalasia. The results suggest that, to exclude pseudoachalasia, additional investigations are warranted when achalasia patients have two or more of these risk factors. The conventional diagnostics for achalasia are not useful for differentiation. Additional testing is not required for achalasia patients that have none or just one risk factor.
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